Sunshine Biopharma, Inc. (SBFM)

USD 2.75

(0.37%)

Market Cap (In USD)

5.49 Million

Revenue (In USD)

24.09 Million

Net Income (In USD)

-4.5 Million

Avg. Volume

163.49 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.106-608.0
PE
-
EPS
-
Beta Value
-1.036
ISIN
US8677814035
CUSIP
867781304
CIK
1402328
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Steve N. Slilaty Ph.D.
Employee Count
-
Website
https://www.sunshinebiopharma.com
Ipo Date
2022-02-15
Details
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.